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Abstract
Background: The renin-angiotensin-aldosterone system (RAS) cascade is a major target for the
clinical management of hypertension. Although inhibitors of various components of this cascade
have been developed successfully, development of renin inhibitors has proven to be problematic.
The development of these inhibitors has been hindered by poor bioavailability and complex
synthesis. However, despite the challenges of designing renin inhibitors, the enzyme remains a
promising target for the development of novel treatments for hypertension. X-ray crystallographic
data could greatly assist the design and development of these inhibitors. Here we describe the
purification and characterization of recombinant human renin for x-ray crystallization studies.
Results: A cDNA encoding the full length of native human preprorenin (406 amino acid residues)
was introduced into the HEK-293 cell line. A clonal cell line expressing prorenin was generated and
grown under serum free conditions in a hollow fiber bioreactor. Prorenin was constitutively
secreted and purified directly from the conditioned medium. Concanavalin A chromatography
effectively enriched and purified prorenin to 90% homogeneity in a single step. Prorenin was
converted to active renin by trypsin digestion to remove the propeptide. Active renin was further
purified using a cation exchange column followed by a gel filtration column. Biochemical
characterization of the recombinant enzyme showed both binding and catalytic properties were
essentially identical to previously reported activities for purified renin. Crystals were grown using
this material in our X-ray structure studies, and high resolution diffraction was obtained.
Conclusion: This present work describes a simple and efficient method for the generation and
purification of active human renin. The protein is highly pure and is suitable for supporting
structural biology efforts.
Background
The renin-angiotensin system (RAS) is a hormone system
that regulates blood pressure and extracellular volume in
the body. The RAS sequentially processes angiotensino-
gen to angiotensin II (Ang II), a peptide hormone that is a
potent vasoconstrictor. Inhibition of RAS components has
been used successfully in the treatment of hypertension,
heart failure and end organ damage. Renin catalyzes the
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first and rate-limiting step of the RAS cascade and renin is
specific for angiotensinogen. Blockade of Ang II produc-
tion by direct inhibition of renin has long been a thera-
peutic goal. Early renin inhibitors, such as enalkiren and
remikiren, were effective in blood pressure lowering.
However, due to poor oral bioavailability, duration of
action, and high costs of synthesis, these early peptidomi-
metic inhibitors never progressed to pivotal clinical stud-
ies [1]. Continued clinical interest in renin has led to the
recent approval of the first renin inhibitor, aliskiren (Tek-
turna™), a non-peptidic inhibitor of renin, which has gen-
erated an interest in finding newer renin inhibitors with
improved profiles.
Renin is a member of the aspartic acid protease family.
The human renin gene encodes for a protein consisting of
406 amino acids. It is proteolytically processed and
secreted as a 384 residue zymogen, prorenin, which con-
tains a 46 amino acid propeptide. The propeptide serves
as an autoinhibitory domain that controls the enzyme
activity. The pro segment must be removed to generate
mature, fully active renin. Prorenin is synthesized princi-
pally by juxtaglomerular cells in the wall of the afferent
arteriole of the kidney and is released into the blood-
stream.
Renin was first purified from animal tissues, including
submaxillary glands and kidneys. Yields were generally
very low. For instance, Yokosawa et al [2] obtained only
440 μg of pure renin from 22 kg of non-cancerous autop-
sied human kidneys. Using recombinant techniques,
renin has been expressed and purified from eukaryotic cell
lines including CHO cells[3,4], mouse L-929 cells, sf9
insect cells [5] and DAMP cells [6]. Active renin had also
been over-expressed in Escherichia coli and successfully
refolded [7-9]. In order to supply enzyme to support our
structure-based design efforts, we developed an efficient
system for renin production and purification in amounts
sufficient to support routine X-ray crystallography.
Herein, we report a simple procedure for renin expression
and purification that exploits the affinity of glycosylated
renin for Con A. Generally, multi-milligram quantities of
material can be prepared from the conditioned medium
of HEK cell culture. The active renin protein prepared has
been used successfully to support activity assays and to
generate high resolution crystal complexes with bound
inhibitors.
Results and discussion
The recombinant human renin gene was transfected into
the human kidney cell line, HEK-293. A clonal cell line
expressing significant levels of prorenin was prepared by
limiting dilution. Analysis of the conditioned media of
multiple clones identified a single clone that was scaled
and transferred to growth in a hollow fiber bioreactor.
This line was subsequently adapted to growth in serum
free media. The recombinant human prorenin was consti-
tutively secreted into the medium with concomitant
removal of the 23 aminoacid long N-terminal signal pep-
tide (Fig. 1a). Although serum-free medium was used to
a. Amino acid sequence of the recombinant human preprorenin Figure 1
a. Amino acid sequence of the recombinant human preprorenin. The underlined 23 residues are the signal sequence (1–23), 
the residues in italics are propeptide (24–66) and the remaining residues are the mature renin protein (67–406). b. SDS-PAGE 
profile of renin purification. Lane 1, Conditioned medium (load to Con A column); Lane 2, Con A flowthrough; Lane 3, Con A 
column wash; Lane 4, Eluted prorenin; Lane 5, Prorenin digested with trypsin.
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grow the cells, the small amounts of other proteins
(mainly BSA, as analyzed on SDS-PAGE gels) were found
as contaminants.
Prorenin has two N-linked glycosylation sites (N71TT) and
(N141GT). The glycosylated prorenin has reasonable affin-
ity for Con A and this interaction was used to purify the
protein to high purity in a single step. To our surprise, the
major contaminating protein, BSA, did not bind to the
Con A resin. The bovine serum had been used in the cul-
ture medium initially when the cell line was adapted to
the serum-free medium and BSA was a major component.
Therefore, the Con A chromatography is more like a step
of prorenin enrichment and any major contaminants
were removed subsequently with cation exchange chro-
matography.
After the hollow fiber bioreactor system was set up for the
prorenin expression, the conditioned medium was col-
lected, about 30 ml a day, which was pooled and loaded
onto the Con A column. For one typical manageable puri-
fication experiment, 250–300 ml containing approxi-
mately 50 mg proteins was used. The column was washed
until the baseline was stabilized. In order to improve the
yields, the column was "soaked and then eluted" with the
buffer containing D-methyl-mannopyranoside at the low
flow rate. Usually, two or three cycles of the soaking/elut-
ing were applied in order to maximize the recovery. The
volume of the pooled materials containing mainly
prorenin (12–18 mg) was reduced to approximately 30
ml by the Millipore ultrafiltration device, followed by acti-
vation and further purification (Fig. 1b). No other detect-
able endogenous Con A binding proteins were observed
by Coomasie stained SDS-PAGE gels.
The Con A material was converted to active renin by diges-
tion with trypsin. Trypsin cleaves after residue Arg66. Con-
ditions were optimized using different temperature, time
and amounts of trypsin. The final conditions were
described in the experimental section and provide mild
proteolysis for quantitative conversion of prorenin to
active renin (Fig. 1b). Prolonged trypsin treatment did not
appear to result in any internal cleavage of the protein,
and generally one hour incubation at 4°C with trypsin
afforded a complete conversion from prorenin to renin
indicating that the propeptide trypsin-cleavage site was
accessible.
After digestion, trypsin was removed with trypsin-inhibi-
tor agarose beads. Any other contaminants or misfolded
renin proteins were removed with cation exchange chro-
matography (SP Sepharose Fast Flow, data not shown).
Approximately 60–70% of the total proteins were
removed at this step. The final step of purification
involved with a size exclusion column, resulting in a puri-
fied activated renin of >98% purity, as estimated by the
reducing SDS-PAGE analysis. The conversion of prorenin
to renin by trypsin results in removal of 46 amino acids,
approximately 5.2 kDa. Because of heterogeneous nature
of glycosylation [10], prorenin and renin migrated on the
SDS-PAGE gel as broad bands of around 50 kDa and 42
kDa, respectively (molecular weight of the DNA-deduced
polypeptides of prorenin and renin were 42,319 and
37,233, respectively, see Table 1). The proteins were ana-
lyzed by the N-terminal sequencing and mass spectrome-
try for further characterization of the proteolytic
activation. The N-terminal sequence analysis confirmed
that the first residues of the mature renin were LTLGXT
and verified the complete removal of the propeptide
(Table 1). The X represents the asparagine residue (N71)
which is a glycosylation site. Mass spectrometry analysis
indicated that glycosylation of renin added from 4 to 7
kDa to the molecular weight, based on the calculated
DNA-deduced amino acid sequence. The discrepancy of
molecular weights might be related to variations in
growth conditions and reagents from batch to batch
because of the heterogeneous nature of glycosylation (oli-
gosaccharides varying in the number of sugar residues).
The sugar moieties were removable by endoglycosidase H
treatment only in partially denatured proteins under con-
ditions of 1% SDS at 37°C overnight (data not shown). In
our crystallization studies and biological assays, the sugar
moieties were not removed. Typically, 1–3 mg of protein
could be obtained from one batch of purification using
approximately 250 – 300 ml starting conditioned
medium (containing 40–50 mg proteins), depending on
cell well-being, growth conditions and other procedural
irregularities.
The activated renin was characterized in a functional assay
(Fig. 2). The catalytic activity was measured using the
commercially available substrate, DABCYL-γAbu-Ile-His-
Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS, which is based
on the angiotensinogen sequence [11]. Velocity of reac-
tion was initially followed by HPLC and exhibited hyper-
bolic dependence on substrate concentration consistent
with Michaelis-Menten kinetics with an apparent KM of
3.6 μM (data not shown). This value is similar to the KM
of 1.5 μM reported in the literature based on the FRET
assay [11]. The catalytic efficiency of recombinant rennin
Table 1: Summary of physical properties.
Protein N-terminal sequencing MALDI-MS
analyzed expected analyzed expected
prorenin LPTDTT LPTDTT 49,580* 42,319
renin LTLGXT LTLGNT 41,068* 37,233
*the representative major molecular weight peak from several batch 
of samples.BMC Biochemistry 2008, 9:19 http://www.biomedcentral.com/1471-2091/9/19
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was determined using the DABCYL-EDANS substrate. The
enzyme had a second order rate constant (kcat/KM) of 4.7
× 105 M-1s-1. This value is close to the published catalytic
efficiency of 6.9 × 105 M-1s-1 [6] and 3 × 105 M-1s-1 [12] for
the cleavage of angiotensinogen tetradecapeptide by puri-
fied human renin [6,12].
Enzymatic activity of the recombinant human renin was
measured in a pH-rate profile. Activity was measured
between pH 5.4 and 9.1 in 0.5 pH units (Fig. 2a, b). The
maximum activity was observed at pH 6.5, similar to puri-
fied human renin [2]. The peak and the shoulder of the
pH profile were similar to those observed for purified
human renin cleaving partially purified human angi-
otensinogen with the maxima at ~6.5 and 8 [13,14].
Several well characterized inhibitors of human renin were
tested with the recombinant enzyme. These inhibitors
included commercially available statines and the small
molecule inhibitor aliskiren. Pepstatin A (Isovaleryl-Val-
Val-Sta-Ala-Sta) is a potent inhibitor of several aspartic
proteases including cathepsin E (IC50 of 0.2 nM [15]),
cathepsin D (IC50 of 0.4 nM [16]) and HIV protease (IC50
of 250 μM [17]). Human renin is poorly inhibited by pep-
statin A (IC50 of 15 μM [18] and 36 μM [19]), while por-
cine renin exhibits sub-micromolar inhibition constants
with this compound (IC50 of 0.32 μM [18] and 0.58 μM
[20]). The recombinant human renin was inhibited by
pepstatin A with an IC50 of 31 ± 4 μM, similar to literature
values (Fig. 2c).
SR 42128 (Isovaleryl-Phe-Nle-Sta-Ala-Sta) is a pepstatin
analog that inhibits human plasma renin activity (PRA)
with the IC50 of 28 nM [21]. The compound is potent
against purified recombinant human renin with an IC50 of
4.0 ± 0.2 nM (Fig. 2c)
The recombinant renin was also inhibited by aliskiren, a
potent human renin inhibitor currently marketed for
hypertension as Tekturna [22]. Aliskiren is selective for
human renin with a reported IC50 of 0.6 nM [23]. In our
hands, IC50 value for recombinant human renin was 0.81
± 0.17 nM (Fig. 2c).
The recombinant renin is indistinguishable from renin
purified from human sources and stable after long term
(up to 3 years or more) storage at -80°C. The material is
suitable for functional assays and X-ray crystallography.
The material had been used to generate >50 renin inhibi-
tor complexes ranging from 1.7Å–2.7Å resolution
(unpublished data). A typical experiment is shown with
VTP24631 (Fig. 3). VTP24631 is a weak inhibitor of IC50
700 nM. Co-crystals of this compound were obtained by
the hanging drop method. These crystals diffracted at
2.5Å. This complex can be used for soaking studies with
Biochemical characterization of recombinant renin Figure 2
Biochemical characterization of recombinant renin. a. The 
pH rate profile of the hydrolysis of DABCYL-γAbu-Ile-His-
Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS with recombinant 
human renin. The optimal pH is around pH 6.5 with a poorly 
defined shoulder at pH 8. b. Full progress curve of the cleav-
age of fluorogenic substrate with recombinant human renin. 
The enzyme (1 nM) was incubated at 37°C with 1 μM DAB-
CYL-γAbu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS 
([S]<<KM). c. Inhibition of recombinant human renin by 
standard inhibitors. The percent inhibition is plotted as a 
function of inhibitor concentration for aliskiren ( ), SR 42128 
( ) and pepstatin ( ). The line through the data is the least 
squares fit to a four parameter equation describing inhibition, 
and the IC50 values determined are 0.8 nM (aliskiren), 4 nM 
(SR 42128) and 31 μM (pepstatin A), respectively.
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potent inhibitors, which readily displace VTP24631 gen-
erating high quality crystals. Details on the structural solu-
tions of VTP24631 and additional structures will be
reported separately.
Conclusion
This present work describes a simple, efficient method for
the production and purification of active human renin.
Recombinant renin can be generated in milligram quanti-
ties via a simple activation/purification sequence. Bio-
chemical properties of the recombinant human renin are
indistinguishable from those reported in the literature for
purified enzyme. Renin inhibitors were active against the
recombinant enzyme with potencies very similar to the
inhibition constants measured for purified human renin.
The material is highly pure and is suitable for supporting
activity assays and structural biology efforts.
Methods
Cloning and cell culture
The gene for recombinant human renin protein (acces-
sion No. AAA60363, 406 amino acid residues) was cloned
by PCR from a kidney cDNA library. The polymerase
chain reaction conditions were optimized using Elongase
polymerase mixture (Invitrogen, Carlsbad, CA) and the
following primers: huRenin-fwd-5'-CGT CTA AGC TTG
CCA CCA TGG ATG GAT GGA GAA GGA TCG-3' and
huRenin-rev-5'-CGG TCA ATT CTA GAC TTC AGC GGG
CCA AGG C-3'. The 5'-sense primer introduced a consen-
sus Kozak translation initiation sequence [24] and a Hind
III restriction site. The 3' antisense primer introduced an
Xba I restriction site and a stop codon for native protein
expression. The PCR product was digested to completion
with Hind III and Xba I (NEB, Beverly, MA) and cloned
into the mammalian expression vector pcDNA3.1 (Invit-
rogen, Carlsbad, CA). The complete renin sequence was
confirmed by DNA sequencing performed by BigDye ter-
minator reaction chemistry for sequence analysis on the
ABI Prism 377 (Kimmel Center Nucleic Acid Facility, Tho-
mas Jefferson University, Philadelphia, PA). Human
embryonic kidney cells, HEK 293 (ATCC, Manassas, VA)
were cultured in Eagle's Minimum Essential Medium, sup-
plemented with 10% fetal bovine serum (Hyclone, South
Logan, UT), 2 mM L-glutamine, and 100 μg/ml penicillin/
streptomycin (Invitrogen, Carlsbad, CA). Transfection
experiments with pcDNA3.1-huRenin were conducted
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to manufacturer's protocols. Stable transfect-
ants were obtained by selection in media supplemented
with Geneticin (800 μg/ml), and single clones were
obtained by limiting dilution. A single clone was scaled
up and introduced into a hollow fiber bioreactor using a
medium sized cartridge with a 5 kD molecular weight cut-
off (Fibercell Systems Inc, Frederick, MD) to trap the
secreted enzyme in the extra-fiber space. Once the cell line
was established in the bioreactor it was adapted incremen-
tally to a serum-free media for HEK-293, SFM4HEK293
(Hyclone, South Logan, UT) which would aid purification
of the protein. Protein was harvested from the extra-fiber
space daily and the cell line was maintained in the biore-
actor for over 6 months with no observable decrease in
protein production.
Protein purification
The clarified conditioned medium (typically 250 – 300
ml), was loaded by gravity at 4°C to a 30 ml Concanavalin
A (Con A) column (Pharmacia/GE Healthcare, Piscata-
way, NJ), which had been equilibrated with Buffer A (25
mM Tris-HCl, pH 7.5, 300 mM NaCl, 0.1 mM CaCl2 and
0.1 mM MnCl2). The column was then connected to the
FPLC system (GE Pharmacia/GE Healthcare, Piscataway,
NJ) and washed with 5 volumes of Buffer A or until the
Renin co-crystals complexed with VTP24631 Figure 3
Renin co-crystals complexed with VTP24631.
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baseline was stabilized. The prorenin protein was eluted
in Buffer A supplemented with 150 mM D-methyl-man-
nopyranoside (Sigma-aldrich, St. Louis, MO) at slow flow
rate (0.5 ml/min) in a "soak/elute" fashion. The propep-
tide was removed by trypsin digestion (1:100 by weight,
trypsin:prorenin) at 4°C for 60 minutes. The reaction was
quenched by the addition of trypsin-inhibitor (from soy-
bean) beads (T0637, Sigma-aldrich, St. Louis, MO). The
activated renin was dialyzed overnight at 4°C against
Buffer B (10 mM sodium acetate, pH 5, and 10 mM
NaCl). This solution was chromatographed on the 50 ml
SP Sepharose Fast Flow column (Pharmacia/GE Health-
care, Piscataway, NJ) using a NaCl gradient (10 mM – 500
mM). Homogeneous renin was obtained after the gel fil-
tration column Superdex 75 HR 10/30 (Pharmacia/GE
Healthcare, Piscataway, NJ). The purified renin in a buffer
containing 20 mM Tris-HCl, pH 7.0 was concentrated to
5 mg/ml, by ultrafiltration using an Amicon stirred cell
(Millipore, MA) with a membrane of 10,000 MWCO
(YM10), and stored at a -80°C freezer until future use. No
deglycosylation was performed.
Protein samples were analyzed by matrix-assisted laser
desorption ionization mass spectrometry (MALDI-MS)
and by Edman's N-terminal sequencing (the Wistar Insti-
tute, University of Pennsylvania, Philadelphia, PA).
SDS-PAGE and protein assays
The protein samples were analyzed using precast NuPage
Novex 4–12% Bis-Tris gels with MES running buffer (Inv-
itrogen, MD). Proteins on the gel became visible after
staining with 0.01% Coomassie Blue R in a solution con-
taining 10% glacial acid and 20% methanol. Protein con-
centrations were measured using Bio-Rad Assay Kit (a
Bradford-based dye binding method [25]), with bovine
serum albumin (BSA) as standard.
Functional assay
The fluorescence resonance energy transfer (FRET) assay
for renin activity was performed essentially as described in
literature [11]. Recombinant human renin (0.3 nM) was
incubated with 1 μM FRET substrate DABCYL-γAbu-Ile-
His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS (AnaSpec,
San Jose, CA) in the 50 mM BES buffer, pH 7.0 containing
0.5 mg/ml BSA, 150 mM NaCl and 2% DMSO. Incuba-
tion was performed at room temperature in a final volume
of 200 μl in white opaque 96-well optiplates (Perk-
inElmer, Wellesley, MA). Fluorescence (λex= 336 nm, λem=
495 nm) was measured repeatedly over extended period
of time (1–2 hrs) on either Victor V or Fusion plate reader
(PerkinElmer, Wellesley, MA), and the intensity of fluo-
rescence was regressed against reaction time to derive
velocities. The reaction rates were used for calculating per-
cent inhibition values using uninhibited renin as a posi-
tive control and either no enzyme or renin inactivated
with 2 μM SR 42128 (Isovaleryl-Phe-Nle-Sta-Ala-Sta)
(Bachem, King of Prussia, PA) as a negative control. IC50
values were calculated by fitting the percent inhibition
values vs. inhibitor concentration into a four-parametric
model using XLFit software (IDBS, Guildford, UK).
Sample preparation and crystallization
The hanging-drop, vapor-diffusion method was used for
renin crystallization. Renin was first mixed with 2 mM
VTP24631 and incubated on ice for 30 minutes. For each
hanging drop, 1 ul of the protein solution was combined
with 0.6 ul of precipitant (0.1 M Tris-HCl, pH 7–8.2, 0.2
mM (NH4)2SO4 and 18–26% PEG 3550). Crystals were
grown at 4°C for 5–7 days and streak seeding was
required for crystals to reach their maximal sizes (200–
500 μm).
Abbreviations
BES: N, N-bis(2-hydroxyethyl)-2-aminoethanesulfonic
acid; BSA: bovine serum albumin.
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